OCS
Oculis Holding AG

79
Mkt Cap
$1.18B
Volume
252,691.00
52W High
$23.08
52W Low
$14.00
PE Ratio
-8.06
OCS Fundamentals
Price
$20.33
Prev Close
$21.55
Open
$21.87
50D MA
$18.65
Beta
0.85
Avg. Volume
22,305.33
EPS (Annual)
-$2.41
P/B
6.54
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?
Oculis Holding AG (OCS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·20d ago
News Placeholder
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·1mo ago
News Placeholder
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -11.32% and +28.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -83.33% and +1.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio (GBIO) delivered earnings and revenue surprises of -11.43% and -51.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·3mo ago
News Placeholder
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of +112.50% and +344.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest OCS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.